1.Memorial Symposium-3: Identification of a Resistance Exercise-Specific Signaling Pathway that Drives Skeletal Muscle Growth
Wenyuan G. ZHU ; Aaron CQ THOMAS ; Gary M WILSON ; Jamie E HIBBERT ; Corey GK FLYNN ; Chris MCGLORY ; Kent W JORGENSON ; Nathaniel D. STEINERT ; Kuan-Hung LIN ; Joshua J. COON ; Stuart M. PHILLIPS ; Troy A. HORNBERGER
Japanese Journal of Physical Fitness and Sports Medicine 2025;74(1):29-29
2.Therapeutic implications of synonymous gene recoding: insights into mechanisms controlling protein biogenesis and activity.
Brian C LIN ; Katarzyna I JANKOWSKA ; Upendra K KATNENI ; Randilu AMARASINGHE ; Nigam PADHIAR ; Nobuko HAMASAKI-KATAGIRI ; Wells W WU ; Haojie ZHU ; Hideki TAGUCHI ; Arnab GHOSH ; David D HOLCOMB ; Je-Nie PHUE ; Sarah E FUMAGALLI ; Darón I FREEDBERG ; Ofer KIMCHI ; Rong-Fong SHEN ; Anton A KOMAR ; Zuben E SAUNA ; Chava KIMCHI-SARFATY
Protein & Cell 2025;16(10):905-910
3.The antitumor activity and mechanisms of piperlongumine derivative C12 on human non-small cell lung cancer H1299 cells
Hai-tao LONG ; Xue LEI ; Jia-yi CHEN ; Jiao MENG ; Li-hui SHAO ; Zhu-rui LI ; Dan-ping CHEN ; Zhen-chao WANG ; Yue ZHOU ; Cheng-peng LI
Acta Pharmaceutica Sinica 2024;59(10):2773-2781
The compound (
4.A new hexacyclic triterpenoid with 13α ,27-cyclopropane ring from Glechoma longituba
Qian ZHANG ; Mei-long LU ; Tian-zi LIU ; Yue-ting ZHANG ; Ao ZHU ; Li-li DING ; Zhu-zhen HAN ; Li-hua GU ; Zheng-tao WANG
Acta Pharmaceutica Sinica 2024;59(5):1334-1340
In order to study the compounds from
5.The intervention effect of Lycium barbarum leaves on letrozole-induced PCOS mice based on microbiome
Xin-yue ZHANG ; Cong LU ; Hui-li ZHENG ; Shu-lan SU ; Yue ZHU ; Sheng GUO ; Da-wei QIAN ; Hong-jie KANG ; Jin-ao DUAN
Acta Pharmaceutica Sinica 2024;59(7):2030-2040
The purpose of this study was to investigate the intervention effect and mechanism of
6.Study on the Effect of Chimeric Virus-like Particles Based on Hepatitis E Virus on Human Papillomavirus Type 16 Tumor Immunotherapy
Kexin ZHANG ; Yun ZHU ; Peikai MA ; Tong AN ; Siqi LI ; Qiantong SHEN ; Gang CHEN ; Yongneng LUO ; Fangchng ZHUANG ; Shaohong LU ; Meng GAO
Chinese Journal of Modern Applied Pharmacy 2023;40(23):3251-3256
OBJECTIVE To study the immunotherapeutic effect of chimeric virus-like particles(VLPs) based on hepatitis E virus(HEV) against human papillomavirus type 16(HPV 16) tumor. METHODS HPV16 E7 was inserted into the p239 protein of HEV to form the recombinant chimeric protein p239-HPV16 E7. The constructed recombinant protein was expressed by Escherichia coli, purified, and then refolded, and the protein was detected by electron microscopy and dynamic light scattering to confirm size and shape. Then, the C57B/L mice were immunized with the protein grain, and the lymphocyte differentiation of mouse spleen was detected by flow cytometry and enzyme-linked immune spot immunoassay; in addition, TC-1 tumor cells were used to construct tumor models in C57B/L mice to evaluate the anti-tumor immune effect of protein particles in mice. RESULTS After refold in vitro, the structure of chimeric protein was observed under electron microscopy, and the size of particle was 22.80 nm. The obtained protein particles induced favorable specific cellular immune response in C57B/L mice. Compared with the control group, the proportions of CD3+/CD4+ and CD3+/CD8+ in spleen lymphocytes of experimental groups were significantly different(P<0.05), and effector T cells secreting IFN-γ interferon were also increased remarkably. At the same time, the obtained protein particles could effectively inhibit the growth of tumor cells in TC-1 tumor-bearing mice, and the mice did not die during the experimental period, while the tumors in the control mice grew rapidly and all died after 6 weeks. CONCLUSION Chimeric protein p239-HPV16E7 which was expressed in prokaryotes can form virus-like particles and effectively induce anti-tumor immunity against HPV16.
7.Development and application of integrated high-throughput microfluidic cell migration chip
Xiao Yang ; Ke Yang ; Chaoru Gao ; Huaqing Zhu ; Ling Zhu
Acta Universitatis Medicinalis Anhui 2023;58(4):581-589
Objective:
To solve the problems of low throughput of current cell migration research methods,which was difficult to establish a stable concentration gradient and observe cell migration behavior in real time,a six-channel array microfluidic chip was designed in this paper.
Methods :
In this paper,a six-channel array microfluidic chip is designed.Firstly,multiphysics modeling and numerical simulation were performed using the finite element analysis software COMSOL Multiphysics 5.5 to analyze the flow behavior of the main pipeline of cell migration. Then,the throughput advantage of the device was verified by testing the chemotaxis response of healthy human neutrophils to different types of chemokine gradients in this microfluidic chip.Subsequently,by analyzing the migration rate of neutrophils in 6 patients with type II diabetes mellitus and 3 healthy people,the clinical applicability of the annular six-channel array microfluidic chip was further verified.Finally,the Pearson coefficient was used to analyze the correlation between neutrophil chemotaxis function and some physiological indicators in patients with diabetes.
Results:
The concentration gradient data inside the pipeline simulated by the simulation software was compatible with the real-time fluorescence test data of the pipeline.The average migration rate of healthy human neutrophils was (0.21 ± 0.01 ) μm / s in 100 nmol / L interleukin-8 ( IL-8 ) environment and (0.22 ± 0.01 ) μm / s in 100 nmol / L N-Formyl-Met-Leu-Phe ( fMLP) environment. In the comparison of neutrophil migration experiments between healthy people and diabetic patients,the chemotaxis rate of neutrophils in healthy people was (0.19 ± 0.01) μm / s ,and the neutrophil chemotaxis rate in diabetic patients was (0. 15 ± 0. 02 ) μm / s. Correlation analysis showed that neutrophil migration rate in patients with type II diabetes mellitus was inversely correlated with glycated hemoglobin.
Conclusion
The high-throughput microfluidic chip proposed in this paper allowed rapid and selective detection of cell migration characteristics at the single-cell level,and it could be used as a new tool for cell migration research.
8.Corynoxine B targets at HMGB1/2 to enhance autophagy for α-synuclein clearance in fly and rodent models of Parkinson's disease.
Qi ZHU ; Juxian SONG ; Jia-Yue CHEN ; Zhenwei YUAN ; Liangfeng LIU ; Li-Ming XIE ; Qiwen LIAO ; Richard D YE ; Xiu CHEN ; Yepiao YAN ; Jieqiong TAN ; Chris Soon HENG TAN ; Min LI ; Jia-Hong LU
Acta Pharmaceutica Sinica B 2023;13(6):2701-2714
Parkinson's disease (PD) is the most common neurodegenerative movement disease. It is featured by abnormal alpha-synuclein (α-syn) aggregation in dopaminergic neurons in the substantia nigra. Macroautophagy (autophagy) is an evolutionarily conserved cellular process for degradation of cellular contents, including protein aggregates, to maintain cellular homeostasis. Corynoxine B (Cory B), a natural alkaloid isolated from Uncaria rhynchophylla (Miq.) Jacks., has been reported to promote the clearance of α-syn in cell models by inducing autophagy. However, the molecular mechanism by which Cory B induces autophagy is not known, and the α-syn-lowering activity of Cory B has not been verified in animal models. Here, we report that Cory B enhanced the activity of Beclin 1/VPS34 complex and increased autophagy by promoting the interaction between Beclin 1 and HMGB1/2. Depletion of HMGB1/2 impaired Cory B-induced autophagy. We showed for the first time that, similar to HMGB1, HMGB2 is also required for autophagy and depletion of HMGB2 decreased autophagy levels and phosphatidylinositol 3-kinase III activity both under basal and stimulated conditions. By applying cellular thermal shift assay, surface plasmon resonance, and molecular docking, we confirmed that Cory B directly binds to HMGB1/2 near the C106 site. Furthermore, in vivo studies with a wild-type α-syn transgenic drosophila model of PD and an A53T α-syn transgenic mouse model of PD, Cory B enhanced autophagy, promoted α-syn clearance and improved behavioral abnormalities. Taken together, the results of this study reveal that Cory B enhances phosphatidylinositol 3-kinase III activity/autophagy by binding to HMGB1/2 and that this enhancement is neuroprotective against PD.
9.Characteristic identification of Sophorae Flavescentis Radix and Sophorae Tonkinensis Radix et Rhizoma based on HPTLC-ESI-MS
Fan LI ; Li-hua GU ; Moo-seob KIM ; Lin-nan LI ; Zhu-zhen HAN ; Li YANG ; Zheng-tao WANG
Acta Pharmaceutica Sinica 2023;58(10):3090-3098
Sophorae Flavescentis Radix is the dried root of
10.Development and validation of a CT-based radiomics model for differentiating pneumonia-like primary pulmonary lymphoma from infectious pneumonia: A multicenter study.
Xinxin YU ; Bing KANG ; Pei NIE ; Yan DENG ; Zixin LIU ; Ning MAO ; Yahui AN ; Jingxu XU ; Chencui HUANG ; Yong HUANG ; Yonggao ZHANG ; Yang HOU ; Longjiang ZHANG ; Zhanguo SUN ; Baosen ZHU ; Rongchao SHI ; Shuai ZHANG ; Cong SUN ; Ximing WANG
Chinese Medical Journal 2023;136(10):1188-1197
BACKGROUND:
Pneumonia-like primary pulmonary lymphoma (PPL) was commonly misdiagnosed as infectious pneumonia, leading to delayed treatment. The purpose of this study was to establish a computed tomography (CT)-based radiomics model to differentiate pneumonia-like PPL from infectious pneumonia.
METHODS:
In this retrospective study, 79 patients with pneumonia-like PPL and 176 patients with infectious pneumonia from 12 medical centers were enrolled. Patients from center 1 to center 7 were assigned to the training or validation cohort, and the remaining patients from other centers were used as the external test cohort. Radiomics features were extracted from CT images. A three-step procedure was applied for radiomics feature selection and radiomics signature building, including the inter- and intra-class correlation coefficients (ICCs), a one-way analysis of variance (ANOVA), and least absolute shrinkage and selection operator (LASSO). Univariate and multivariate analyses were used to identify the significant clinicoradiological variables and construct a clinical factor model. Two radiologists reviewed the CT images for the external test set. Performance of the radiomics model, clinical factor model, and each radiologist were assessed by receiver operating characteristic, and area under the curve (AUC) was compared.
RESULTS:
A total of 144 patients (44 with pneumonia-like PPL and 100 infectious pneumonia) were in the training cohort, 38 patients (12 with pneumonia-like PPL and 26 infectious pneumonia) were in the validation cohort, and 73 patients (23 with pneumonia-like PPL and 50 infectious pneumonia) were in the external test cohort. Twenty-three radiomics features were selected to build the radiomics model, which yielded AUCs of 0.95 (95% confidence interval [CI]: 0.94-0.99), 0.93 (95% CI: 0.85-0.98), and 0.94 (95% CI: 0.87-0.99) in the training, validation, and external test cohort, respectively. The AUCs for the two readers and clinical factor model were 0.74 (95% CI: 0.63-0.83), 0.72 (95% CI: 0.62-0.82), and 0.73 (95% CI: 0.62-0.84) in the external test cohort, respectively. The radiomics model outperformed both the readers' interpretation and clinical factor model ( P <0.05).
CONCLUSIONS
The CT-based radiomics model may provide an effective and non-invasive tool to differentiate pneumonia-like PPL from infectious pneumonia, which might provide assistance for clinicians in tailoring precise therapy.
Humans
;
Retrospective Studies
;
Pneumonia/diagnostic imaging*
;
Analysis of Variance
;
Tomography, X-Ray Computed
;
Lymphoma/diagnostic imaging*


Result Analysis
Print
Save
E-mail